• Extensive stage SCLC (Es-SCLC)
• Extensive stage SCLC (Es-SCLC) - maintenance (M) 2
• Extensive stage SCLC (Es-SCLC) - 1st Line (L1) 5
• Extensive stage SCLC (Es-SCLC) - 2nd line (L2)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab plus SoC
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus SoC
• durvalumab based treatment
• durvalumab plus etoposide and platin
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• durvalumab plus tremelimumab plus SoC
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs etoposide plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs HER inhibitor
• vs HER2 inhibitor
• vs pertuzumab based treatment
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs placebo;   vs placebo plus SoC;   vs etoposide plus platin; 
Risk of bias:  low;   some concerns;   high;  NA;